Lipocine Q3 EPS $(0.08) Beats $(0.32) Estimate, Sales $2.290M Beat $159.500K Estimate
Benzinga Newsdesk 1 day ago
NewsEarningsEarnings Beats
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.32) by 75 percent. This is a 86.44 percent increase over losses of $(0.59) per share from the same
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.32) by 75 percent. This is a 86.44 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $2.290 million which beat the analyst consensus estimate of $159.500 thousand by 1.34K percent. This is a 1.90K percent increase over sales of $114.574 thousand the same period last year.